about
Enhanced effect of microdystrophin gene transfection by HSV-VP22 mediated intercellular protein transportClinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up.Delay in diagnosis of muscle disorders depends on the subspecialty of the initially consulted physicianExploration of lipid metabolism in relation with plasma membrane properties of Duchenne muscular dystrophy cells: influence of L-carnitineA novel functional assessment of the differentiation of micropatterned muscle cells.Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophy.The molecular era of myology.PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy.The interface of genomic technologies and nursing.Well-devised quantification analysis for duplication mutation of Duchenne muscular dystrophy aimed at preimplantation genetic diagnosisTherapeutics in duchenne muscular dystrophy.Gene therapy for muscular dystrophy: current progress and future prospects.Targeted gene therapy for the treatment of heart failure.Marking the tempo for myogenesis: Pax7 and the regulation of muscle stem cell fate decisionsIn vivo fusion of circulating fluorescent cells with dystrophin-deficient myofibers results in extensive sarcoplasmic fluorescence expression but limited dystrophin sarcolemmal expression.The GTPase RhoA increases utrophin expression and stability, as well as its localization at the plasma membraneAndrographolide attenuates skeletal muscle dystrophy in mdx mice and increases efficiency of cell therapy by reducing fibrosis.Macrophage-secreted factors enhance the in vitro expansion of DMD muscle precursor cells while preserving their myogenic potential.NO more muscle fatigue.Con: Greater funding of cell and molecular biology has not delivered what was promised to respiratory medicine.The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.
P2860
Q33290259-47CC18FA-C307-4F08-8A9B-EC2D13D17637Q33405753-48B36329-1801-43F5-8DCA-F6C8EF31071AQ33889971-963FE5BA-6DB6-4C65-83B8-E03034D27172Q34499637-8C0A230C-19BE-4D73-B78D-08ED728125EAQ34600250-35CEC66B-A76B-41F4-9C4B-DA8DF57D3676Q35549208-2C6BB542-9BEE-413E-9C74-8FD1C68C580EQ35614903-41AEB390-25D7-42D2-8AEB-ED59E3198578Q35720854-294A1636-C0A4-415D-8060-76C85FE8272FQ36165043-55225117-3E70-4DB4-8103-42D70AF96E2BQ36268493-04C60958-0351-46F3-8781-34A4869EB26AQ36428758-5992E0E0-AE18-4EBB-8335-AE144206258EQ37519650-D33B3D08-BB8E-4CD8-9432-A76F351DD613Q37878086-59A9C3F1-24A8-4814-A73E-CB107E22DBD7Q37880238-C2551720-C17A-4FF0-95A0-6F65FCB19FCEQ38586086-6DAFBBC5-1356-400A-B36B-E4E79C4288C1Q39497947-2D8861D9-69F3-4EB0-AB5B-BCD87A43A763Q39629598-6D99EA02-A7E6-4F57-A39A-043A01F572DFQ39901699-53675927-F429-42FB-8FF9-C107AFB43E59Q43172685-260F277C-98C6-46CC-8C07-8AFB91046BE4Q48022258-D91BF058-7015-429E-9751-BD0BFD0CBFC7Q52738891-19A85C7E-19EF-4095-8032-DD14600185C7
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Novel therapies for Duchenne muscular dystrophy.
@ast
Novel therapies for Duchenne muscular dystrophy.
@en
type
label
Novel therapies for Duchenne muscular dystrophy.
@ast
Novel therapies for Duchenne muscular dystrophy.
@en
prefLabel
Novel therapies for Duchenne muscular dystrophy.
@ast
Novel therapies for Duchenne muscular dystrophy.
@en
P2093
P1433
P1476
Novel therapies for Duchenne muscular dystrophy.
@en
P2093
Andrew J Kornberg
Edward Byrne
Robert Kapsa
P304
P356
10.1016/S1474-4422(03)00382-X
P577
2003-05-01T00:00:00Z